Drugs / Trivalent Salmonella Conjugate Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05784701 Comparator | Apr 2023 → Jan 2027 expected | — | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Salmonella Conjugate Vaccine | “This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV).” NCT05784701 ↗ |
| Known as | TSCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05784701 ↗ |
| Modality | Vaccine | “Trivalent Salmonella Conjugate Vaccine (TSCV)” NCT05784701 ↗ |